You just read:

Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder

News provided by

Eli Lilly and Company

Dec 05, 2013, 08:00 ET